Elastic NV vs Novavax Inc — how do they compare? Elastic NV trades at $97.68 (market cap $10.00B), while Novavax Inc trades at $12.83 (market cap $1.82B). The key difference: Elastic NV is far larger — about 5.5× Novavax Inc's market cap, and Novavax Inc is more actively traded (6,198,505 versus 1,610,337). Which is the better fit depends on your goals — on Pluang, investors hold Elastic NV for 10 Days and Novavax Inc for 59 Days on average.
| ESTC | NVAX | |
|---|---|---|
Market Cap | $10.00B | $1.82B |
Volume | 1,610,337 | 6,198,505 |
Sector | Technology | Health |
52-Week High | $99.91 | $12.56 |
52-Week Low | $43.30 | $6.22 |
Typical Hold Time | 10 Days | 59 Days |
Enterprise Value | $9.14B | $1.39B |
Signals from Pluang's Aura AI — not financial advice
Elastic (ESTC) trades at $97.54, up 4.77% on the day, reflecting strong momentum as it approaches resistance near $98. The stock exhibits a bullish technical setup with moving averages supporting the uptrend, though the short-term RSI indicates potential overbought conditions. Fundamentally, the company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue growth is robust, projected to rise from $1.48 billion in 2025 to $1.8 billion in 2026, while net income is expected to swing from a loss to a $376 million profit, signaling improving profitability. Recent news highlights product innovations in AI and observability platforms, reinforcing its competitive edge.
The outlook for ESTC is positive, driven by earnings beats, solid revenue expansion, and strategic product launches in high-growth areas like AI and data search. Key risks include high valuation multiples, such as a P/E of 27.22 and EV/EBITDA of 496.59, which may limit upside if growth slows. Analyst consensus is strongly bullish with a 64.71% buy rating, though the average price target of $79.50 suggests caution relative to the current price. Investors should weigh the strong fundamental trajectory against valuation concerns and market volatility.
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Elastic NV provides a leading search AI platform built on Elasticsearch. Its software helps organizations find, observe, and protect data through search-powered analytics for various cloud-based applications.
Read more on ESTC →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →